Panacea Global’s Early Cancer Detection Automated Testing Platform
Mon, 10 Feb 2014
(February 10, 2014)
Panacea Global, Inc. (Panacea)
Panacea Global’s Early Cancer Detection Test now offered on an Automated Testing Platform
A biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, announced today the development of a fully automated device for commercialization of its early cancer diagnostics test.
Panacea Global newly designed ELISA machine is a custom-designed, fully-automated solution to detect the presence of HAAH, a novel biomarker present in cancer patients’ blood samples. With minimal operator interference, the device manages all aspects of the test protocol with the highest degree of conformity. The automation is currently capable of managing over 1000 patients per day. A series of hardware and accompanying software ensure that both accuracy and reproducibility of Panacea’s test is maintained at its highest level.
The newly developed customized and automated system will allow Panacea Global commercialization of our cutting-edge early cancer marker on a global scale, said Dr. Mahmood Moshiri, Panacea’s President and CEO. “The device will allow us and our partners to saves time and resources, eliminate human errors, and ensure high-quality results. Furthermore, the automation allows for stronger management of patient identification throughout the process. This reduces the opportunity for misdiagnosis and mislabeling.”
About Panacea Global
Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea’s test is based on the detection of the human aspartyl (asparaginyl) ?-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients’ blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (OTCBB: PANG) is available at www.panaceaglobalinc.com.
Certain information contained in this document may include forward-looking information. Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as may, would, could, will, likely, believe, expect, anticipate, intend, plan, estimate and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management’s good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.